CN1593411A - Speckle removing pharmaceutical composition - Google Patents
Speckle removing pharmaceutical composition Download PDFInfo
- Publication number
- CN1593411A CN1593411A CN 200410015958 CN200410015958A CN1593411A CN 1593411 A CN1593411 A CN 1593411A CN 200410015958 CN200410015958 CN 200410015958 CN 200410015958 A CN200410015958 A CN 200410015958A CN 1593411 A CN1593411 A CN 1593411A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- cysteine
- drug combination
- derivatives
- removing freckles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Disclosed is a speckle removing pharmaceutical composition comprising vitamin C or one or more of vitamin C derivatives, cysteine or one or more of cysteine salts, pantothenic acid or one or more ofpantothenic acid salts, vitamin B6 and medicinal findings.
Description
Technical field
The present invention relates to a kind of cosmetics, relate in particular to a kind of drug combination for removing freckles.
Background technology
How to improve cutaneous pigmentation, be a difficult problem of beauty treatment circle and even department of dermatologry educational circles always.Facial pigmented spots has numerous species, as freckle, chloasma, senile plaque etc., also has congenital pigment macle, wherein sees so that chloasma more.
Show that according to studying for a long period of time of aesthetic medicine man facial speckle mainly is owing to generation is concentrated, deposited to the melanin that the solarization of burning summer, endocrine disturbance, acne and sore healing are retained in skin substrate aspect.On biochemistry, melanin is a kind of hmw protein with poly-quinone structure.Melanic formation will be through the metabolic processes of a series of complexity, mainly be that tyrosine becomes DOPA gradually under the effect of tryrosinase, DOPA quickens to become the DOPA quinone again under the tryrosinase effect, then---dopachrome---DHI---quinoid indole forms melanin at last to develop into the non-pigment material.Therefore, regulate the active substance of tyrosinase activity,, can generate approach by changing melanin, the performance spot-removal function as vitamin and derivant, aminothiopropionic acid and its esters etc.
Cysteine is a kind of important amino acid of forming beta keratin, it extensively is present in the human body skin, can improve the elasticity and the organizational structure of skin, can suppress the effect that melanin generates necessary tryrosinase, make melanin be difficult to produce, thereby suppress melanic excessive generation.In addition, cysteine can help skin metabolism normalization, has the antianaphylaxis effect.The damage that cysteine also can avoid X-ray and nuclear ray to cause.
Vitamin takes off the approval that has obtained the expert except that the effect of melanin skin care skin Caring.Wherein, vitamin C not only can suppress melanic generation, but also has redox, and a large amount of vitamin Cs can make the darker oxidized form pigment of color revert to light color even colourless state gradually; Vitamin B6 promotes the metabolism of skin, mucosa, has the effect of taking off except that the melanin spot; Pantothenic acid can be blocked melanic formation, and helps vitamin C to play a role, thereby improves spot-removal function.
Spot-eliminating beauty treatment product in the market is a lot, but great majority just start with from the surface, and on the face spot is played the coverage effect, can not cure the symptoms, not the disease from the preventing and treating of melanin and spot generation at all.
Summary of the invention
The object of the present invention is to provide a kind of melanin that can effectively suppress to produce, improve Pigmented drug combination for removing freckles.
A kind of drug combination for removing freckles, form by following component: one or more in vitamin C or the vitamin C derivatives, one or more of cysteine or cysteine salt apoplexy due to endogenous wind, one or more of pantothenic acid or pantothenate apoplexy due to endogenous wind, vitamin B6 and pharmaceutically useful adjuvant; Wherein the weight ratio of vitamin C or vitamin C derivatives and cysteine or cysteine salt is 1: 0.01～1: 10, preferred 1: 0.1～1: 1, the weight ratio of vitamin C or vitamin C derivatives and pantothenic acid or pantothenic acid salt is 1: 0.008～1: 0.8, preferred 1: 0.04～1: 0.4, the weight ratio of vitamin C or vitamin C derivatives and vitamin B6 is 1: 0.002～1: 0.2, preferred 1: 0.01～1: 0.1; Vitamin C derivatives is sodium ascorbate, vitamin C phosphoric ester, sodium isoascorbate, vitamin C cellulose; The cysteine salt is L-cysteine, cysteine hydrochloride monohydrate, cysteine hydrochloride anhydride; The pantothenic acid salt is calcium pantothenate, sodium pantothenate, dextro calcium pantothenate, sodium dextropantothenate; Drug combination for removing freckles of the present invention can be made tablet or capsule.
A kind of drug combination for removing freckles of the present invention, start with from the approach that melanin produces, fundamentally go to prevent and treat the generation of spot, the effect of performance speckle dispelling, decompose pigmentation, desalination melanin converts established melanin to colourless state, balance skin secretory function, suppress the dopamine enzyme and overlap, help hydrolysising protease new life, promote that melanin decomposes fast, improve local blood capillary circulation, promote skin metabolism, promote self resistivity of cell, eliminate skin pigment undesirable element, gloomy thick black, it is delicate to recover skin.
The specific embodiment
Further specify the present invention below by specific embodiment, but the present invention is not limited by embodiment.
Embodiment 1: the pharmaceutical composition of present embodiment Chinese medicine prepares tablet by methods known in the art, and every contains following composition:
L-cysteine 120mg
Vitamin C 150mg
Vitamin B6 6mg
Calcium pantothenate 24mg
Low-substituted hydroxypropyl cellulose 10mg
Microcrystalline Cellulose 20mg
Add up to 330mg
If desired, tablet can also be wrapped contagion gown.
Embodiment 2: present embodiment Chinese medicine compositions prepares capsule according to methods known in the art, contains following composition in each capsule:
L-cysteine 80mg
Vitamin C 300mg
Vitamin B6 6mg
Calcium pantothenate 15mg
Micropowder silica gel 4mg
Add up to 405mg
Claims (10)
1, a kind of drug combination for removing freckles, it is characterized in that forming: one or more in vitamin C or the vitamin C derivatives by following component, one or more of cysteine or cysteine salt apoplexy due to endogenous wind, one or more of pantothenic acid or pantothenate apoplexy due to endogenous wind, vitamin B6 and pharmaceutically useful adjuvant; Wherein the weight ratio of vitamin C or vitamin C derivatives and cysteine or cysteine salt is 1: 0.01～1: 10, the weight ratio of vitamin C or vitamin C derivatives and pantothenic acid or pantothenic acid salt is 1: 0.008～1: 0.8, and the weight ratio of vitamin C or vitamin C derivatives and vitamin B6 is 1: 0.002～1: 0.2.
2, a kind of drug combination for removing freckles according to claim 1, the weight ratio that it is characterized in that vitamin C or vitamin C derivatives and cysteine or cysteine salt is 1: 0.1～1: 1.
3, a kind of drug combination for removing freckles according to claim 1, the weight ratio that it is characterized in that vitamin C or vitamin C derivatives and pantothenic acid or pantothenic acid salt is 1: 0.04～1: 0.4.
4, a kind of drug combination for removing freckles according to claim 1, the weight ratio that it is characterized in that vitamin C or vitamin C derivatives and vitamin B6 is 1: 0.01～1: 0.1.
5, a kind of drug combination for removing freckles according to claim 1 is characterized in that vitamin C derivatives is sodium ascorbate, vitamin C phosphoric ester, sodium isoascorbate, vitamin C cellulose.
6, a kind of drug combination for removing freckles according to claim 1 and 2 is characterized in that the cysteine salt is L-cysteine, cysteine hydrochloride monohydrate, cysteine hydrochloride anhydride.
7,, it is characterized in that the pantothenic acid salt is calcium pantothenate, sodium pantothenate, dextro calcium pantothenate, sodium dextropantothenate according to claim 1 or 3 described a kind of drug combination for removing freckles.
8, a kind of drug combination for removing freckles according to claim 1 is characterized in that making tablet or capsule.
9, according to claim 1 or 8 described a kind of drug combination for removing freckles, it is characterized in that containing in every tablet of tablet L-cysteine 120mg, vitamin C 150mg, vitamin B6 6mg, calcium pantothenate 24mg, pharmaceutically useful adjuvant low-substituted hydroxypropyl cellulose 10mg and microcrystalline Cellulose 20mg.
10,, it is characterized in that containing in every capsules L-cysteine 80mg, vitamin C 300mg, vitamin B6 6mg, calcium pantothenate 15mg, pharmaceutically useful adjuvant micropowder silica gel 4mg according to claim 1 or 8 described a kind of drug combination for removing freckles.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410015958 CN1593411A (en) | 2004-01-15 | 2004-01-15 | Speckle removing pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410015958 CN1593411A (en) | 2004-01-15 | 2004-01-15 | Speckle removing pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1593411A true CN1593411A (en) | 2005-03-16 |
Family
ID=34663037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410015958 Pending CN1593411A (en) | 2004-01-15 | 2004-01-15 | Speckle removing pharmaceutical composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1593411A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101002765B (en) * | 2006-01-16 | 2011-10-12 | 日商·爱诗爱诗制药股份有限公司 | Compressed formed preparation |
| CN102552247A (en) * | 2012-03-07 | 2012-07-11 | 常州市第四制药厂有限公司 | Composition of vitamin C and preparation method thereof |
-
2004
- 2004-01-15 CN CN 200410015958 patent/CN1593411A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101002765B (en) * | 2006-01-16 | 2011-10-12 | 日商·爱诗爱诗制药股份有限公司 | Compressed formed preparation |
| CN102552247A (en) * | 2012-03-07 | 2012-07-11 | 常州市第四制药厂有限公司 | Composition of vitamin C and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9162084B2 (en) | Formulations for topical delivery of bioactive substances and methods for their use | |
| JP4033877B2 (en) | Composition for promoting type I collagen production | |
| EP2178818B1 (en) | Treatments using vitamin k analogues and derivatives | |
| US20050266064A1 (en) | Cosmetic compositions and methods | |
| KR20180021784A (en) | Nicotinamide riboside and phthalostilbene compositions and methods for the treatment of dermatoses | |
| KR20190046895A (en) | Nicotinamide riboside and thermostyrene compositions and methods for the treatment of neurodegenerative diseases | |
| ES2606392T3 (en) | Compositions comprising omega-3 and vitamin D fatty acids for acne vulgaris and / or eczema, and procedures and uses thereof | |
| BRPI0614091A2 (en) | solid extended release pharmaceutical composition containing carbidopa and levodopa | |
| CN108135972B (en) | Application of mussel mucin product in treating and preventing melanin-related diseases | |
| US8529879B2 (en) | Epithelium-improving agent | |
| US20070167517A1 (en) | Stabilized derivatives of ascorbic aicd | |
| EP0387756B1 (en) | Use of 5'-deoxy-5'-methylthioadenosine s-adenosylmethionine and their salts in the preparation of seborrhea-reducing pharmaceutical compositions | |
| KR20090103992A (en) | Use of gamma-amino butyric acid as a depigmenting agent | |
| WO2004075849A2 (en) | Method and composition for treating hypopigmentation of the hair and skin | |
| CN1593411A (en) | Speckle removing pharmaceutical composition | |
| Humbert et al. | Vitamin c, aged skin, skin health | |
| WO2008114082A1 (en) | Methods, processes and compositions comprising the protein calmodulin (cam) for treatment of damaged or ageing skin, and/or hair loss | |
| JP2014210762A (en) | Sebum secretion inhibitor | |
| JP2005170834A (en) | Skin ameliorating preparation | |
| JP2017066080A (en) | External composition | |
| CN104825451A (en) | Vitamin B3 sustained release preparation for whitening and removing freckles | |
| KR102047193B1 (en) | Skin external composition and photodynamic therapy composition for prevention and treatment of pimples comprising glutamylamidoethylindole | |
| Singh et al. | Efficacy of Ferulic Acid Peel as a Monotherapy for Photoaging | |
| Newaj | What to do about hyperpigmentation? | |
| Humbert et al. | The Action of Vitamin C for Treating Wrinkles and Protecting Skin from Photodamage. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |